SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 380.70 |
Enterprise Value ($M) | 364.65 |
Book Value ($M) | 58.97 |
Book Value / Share | 0.66 |
Price / Book | 6.46 |
NCAV ($M) | 57.40 |
NCAV / Share | 0.64 |
Price / NCAV | 6.63 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.74 |
Return on Assets (ROA) | -0.50 |
Return on Equity (ROE) | -0.54 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.38 |
Current Ratio | 7.38 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 67.34 |
Assets | 68.91 |
Liabilities | 9.94 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Venrock Healthcare Capital Partners II, L.P. | 9.99 | 14.45 | |
13G/A | Rubric Capital Management LP | 6.92 | -11.57 | |
13D/A | New Enterprise Associates 16, L.P. | 18.70 | 0.00 | |
13G/A | Frazier Life Sciences Public Fund, L.P. | 10.20 | 10.77 | |
13G/A | Rosalind Advisors, Inc. | 1.03 | -46.10 | |
13G/A | MAI Capital Management | |||
13G/A | Fairmount Funds Management LLC | 0.00 | -100.00 | |
13G/A | Viking Global Investors Lp | 9.99 | 7.09 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
53,679 | 442,594 | 12.13 | |
23,172 | 231,459 | 10.01 | |
50,620 | 874,594 | 5.79 | |
36,247 | 282,462 | 12.83 | |
78,881 | 784,281 | 10.06 | |
(click for more detail) |
Similar Companies | |
---|---|
TLPH – Talphera, Inc. | TNGX – Tango Therapeutics, Inc. |
TRDA – Entrada Therapeutics, Inc. | TSBX – Turnstone Biologics Corp. |
TVTX – Travere Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io